NeoGenomics (NEO) Tops Q1 EPS by 2c, reaffirms outlook

NeoGenomics (NASDAQ: NEO) reported Q1 EPS of ($0.02), $0.02 better than the analyst estimate of ($0.04). Revenue for the quarter came in at $156 million versus the consensus estimate of $149.89 million.

GUIDANCE:

NeoGenomics sees FY2024 revenue of $650-660 million, versus the consensus of $654.7 million.

For earnings history and earnings-related data on NeoGenomics (NEO) click here.

You May Also Be Interested In

• Okta upgraded as AI security opportunity boosts outlook
• Bernstein SocGen on Intuitive Surgical (ISRG): 'We see $400 as a great entry point'
• Dyadic International, Inc. (DYAI) Misses Q2 EPS by 2c